Luteolin

SKU: orb1310014

Description

Luteolin is a naturally occurring flavonoid that acts as an Nrf2 and PDE inhibitor. It exhibits a broad spectrum of bioactivities, including antitumor, anti-inflammatory, and antimicrobial effects, making it a valuable tool for in vitro and in vivo research in oncology, immunology, and pharmacology.

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research

Key Properties

• CAS Number: 491-70-3
• MW: 286.24
• Purity: 99.71% (May vary between batches)
• Formula: C₁₅H₁₀O₆
• SMILES: O=C1C=C(OC=2C=C(O)C=C(O)C12)C=3C=CC(O)=C(O)C3
• Target: Endogenous Metabolite,Apoptosis,PDE,Autophagy,Nrf2
• Solubility: Ethanol:3 mg/mL (10.48 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5.7 mg/mL (19.91 mM);DMSO:126.25 mg/mL (441.06 mM)

Bioactivity

• Target IC50:
  PDE1:15.0 μM (Ki)|PDE4:11.1 μM (Ki)|PDE5:9.5 μM (Ki)|PDE3:13.9 μM (Ki)|PDE2:6.4 μM (Ki)
• In Vivo:
  METHODS: To detect anti-tumor activity in vivo, Luteolin (50 mg/kg) was injected intraperitoneally once daily for eighteen days into BALB/C-nu mice bearing ESCC tumor EC1. RESULTS: The Luteolin treatment group showed a reduction in tumor size and a reduction in total tumor weight of about 65%. METHODS: To study the effect on intestinal mucositis, Luteolin (3-30 mg/kg in water plus 1% Tween) was administered by gavage or intraperitoneally to irinotecan-induced intestinal mucositis in Swiss mice once a day for fourteen days. RESULTS: Luteolin prevented irinotecan-induced intestinal damage by reducing weight loss and diarrhea scores as well as attenuating duodenal and colonic shortening.
  Read more...
• In Vitro:
  METHODS: ESCC cell lines EC1, EC9706, KYSE30 and KYSE450 were treated with Luteolin (10-80 µM) for 48-72 h. Cell viability was measured using the CCK-8 Assay. RESULTS: Luteolin inhibited the growth of ESCC cell lines in a dose-dependent manner with IC50 in the range of 20-60 µM. METHODS: Human cervical cancer cells, HeLa, were treated with Luteolin (5-20 µM) for 48 h. Cell cycle profiles were analyzed using Flow Cytometry. RESULTS: Luteolin treatment blocked the cell cycle progression of HeLa cells in sub-G1 phase.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Apoptosis, Autophagy, Digitoflavone, Keap1-Nrf2, inhibit, Luteolin, Luteoline, Luteolol, PDE1, PDE2, PDE3, PDE4, Inhibitor, EndogenousMetabolite, Endogenous Metabolite, Flacitran, PDE5

Compound Identifiers

PubChem CID

5280445